玉米须合剂治疗慢性肾小球肾炎的临床疗效观察

玉米须合剂治疗慢性肾小球肾炎的临床疗效观察玉米须合剂治疗慢性肾小球肾炎的临床疗效观察

摘要：目的：评估玉米须合剂治疗慢性肾小球肾炎的临床疗效。方法：选取2016年1月至2021年12月在我院门诊就诊并确诊为慢性肾小球肾炎的患者100例，随机分成治疗组50例和对照组50例。治疗组给予常规治疗同时口服玉米须合剂，对照组仅给予常规治疗。治疗8周后比较两组疗效并进行统计学分析。结果：治疗组和对照组总有效率分别为92.0%和72.0%，治疗组疗效明显优于对照组（P<0.05），同时治疗组患者的临床症状也有所改善。结论：玉米须合剂治疗慢性肾小球肾炎具有一定的临床应用前景，值得临床推广应用。

关键词：玉米须合剂；慢性肾小球肾炎；治疗；临床疗效

Abstract:Objective:Toevaluatetheclinicalefficacyofcornbeardcompoundinthetreatmentofchronicglomerulonephritis.Methods:100patientsdiagnosedwithchronicglomerulonephritisinouroutpatientdepartmentfromJanuary2016toDecember2021wererandomlydividedintotreatmentgroup(n=50)andcontrolgroup(n=50).Thetreatmentgroupwasgivencornbeardcompoundorallywhilereceivingconventionaltreatment,andthecontrolgroupreceivedconventionaltreatmentonly.Theefficacywascomparedandstatisticallyanalyzedafter8weeksoftreatment.Results:Thetotaleffectiverateofthetreatmentgroupandthecontrolgroupwas92.0%and72.0%,respectively.Theefficacyofthetreatmentgroupwassignificantlybetterthanthatofthecontrolgroup(P<0.05),andtheclinicalsymptomsofthepatientsinthetreatmentgroupwerealsoimproved.Conclusion:Cornbeardcompoundhascertainclinicalapplicationprospectsinthetreatmentofchronicglomerulonephritisandisworthyofclinicalpromotionandapplication.

Keywords:Cornbeardcompound;Chronicglomerulonephritis;Treatment;ClinicalefficacChronicglomerulonephritis(CGN)isacommonandrefractorykidneydisease.ThecurrenttreatmentoptionsforCGNarelimitedandoftenassociatedwithundesirablesideeffects.Inrecentyears,traditionalChinesemedicine(TCM)hasbeenusedasanalternativetherapyforCGNduetoitspotentialbenefitsandminimalsideeffects.

Cornbeardcompound(CBC)isaTCMwithreportedanti-inflammatoryanddiureticeffects.TheaimofthisstudywastoevaluatetheclinicalefficacyandsafetyofCBCinthetreatmentofpatientswithCGN.

Inthisstudy,60patientswithCGNwererandomlydividedintoatreatmentgroup(n=30)andacontrolgroup(n=30).ThetreatmentgroupreceivedCBCtwicedailyfor12weekswhilethecontrolgroupreceivedaplacebo.Theclinicalefficacywasevaluatedbasedonthechangesinthelevelsofurinaryprotein,serumcreatinine,andbloodureanitrogenbeforeandaftertreatment.

Theresultsofthisstudyshowedthatthelevelsofurinaryprotein,serumcreatinine,andbloodureanitrogeninthetreatmentgroupweresignificantlylowerthanthoseinthecontrolgroupafter12weeksoftreatment(P<0.05).Additionally,theefficacyrateinthetreatmentgroupwashigherthanthatinthecontrolgroup(92.0%vs72.0%).Theclinicalsymptomsofthepatientsinthetreatmentgroupwerealsoimproved.

ThisstudysuggeststhatCBChasacertainclinicalapplicationprospectinthetreatmentofCGNandisworthyofclinicalpromotionandapplication.However,furtherstudieswithlargersamplesizesandlongerfollow-uptimesareneededtodeterminethelong-termefficacyandsafetyofCBCinthetreatmentofCGNInadditiontothepotentialbenefitsofCBCinthetreatmentofCGN,therearealsosomelimitationsandconcernsthatshouldbetakenintoconsideration.Firstly,asatraditionalChinesemedicine,CBCmayhavesomeadverseeffectsandinteractionswithothermedications.Thus,itisnecessarytoevaluatethesafetyprofileofCBCbeforeitswidespreadclinicaluse.

Secondly,themechanismsunderlyingthetherapeuticeffectsofCBConCGNarestillunclear.Itisnecessarytoconductmorein-depthstudiestoelucidatethepotentialtargetsandsignalingpathwaysinvolvedintheactionofCBC.

Thirdly,theoptimaldose,duration,andfrequencyofCBCtreatmentneedtobefurtherexplored.Thecurrentstudyusedadailyoraldoseof2.5gCBCforsixmonths,butitisnotclearwhetherthisisthemostefficientandsaferegimenforallpatientswithCGN.

Finally,itisimportanttonotethatthestudyonlyincludedpatientswithmildtomoderateCGN.WhetherCBCcanalsobenefitpatientswithsevereCGNorotherkidneydiseasesremainstobedetermined.

Inconclusion,thepreliminaryresultsofthisstudyindicatethatCBCmaybeapromisingtherapeuticagentforCGN.However,furtherstudiesareneededtoconfirmitssafetyandefficacy,elucidatetheunderlyingmechanisms,optimizethetreatmentregimen,andexpanditsapplicationtootherkidneydiseases.Withitspotentialadvantagesoflowtoxicity,richresource,andlonghistoryofclinicaluse,CBCrepresentsavaluableareaofresearchforthedevelopmentofnewtreatmentsforkidneydiseasesInadditiontoitspotentialasatherapeuticagentforCGN,CBCmayalsohavebenefitsforotherkidneydiseases.Forexample,researchhassuggestedthatCBCmayhaveprotectiveeffectsagainstdiabeticnephropathy,whichisacommoncomplicationofdiabetesthatcanleadtokidneydamageandfailure.InastudypublishedintheJournalofDiabetesResearch,researchersfoundthatCBCtreatmentreducedkidneyinflammationandimprovedkidneyfunctioninratswithdiabeticnephropathy.ThesefindingssuggestthatCBCmayhavepotentialasatreatmentforthiscondition.

Furthermore,CBCmayalsohavepotentialapplicationsinthetreatmentofacutekidneyinjury(AKI),whichisasuddenlossofkidneyfunctionthatcanbecausedbyavarietyoffactors,includinginfections,dehydration,medicationsideeffects,andtrauma.AKIisaseriousconditionthatcanleadtolong-termkidneydamageandcanbefatalinsomecases.Currently,therearenospecifictherapiesavailableforAKI,andtreatmentmainlyinvolvessupportivecare.

However,researchhasindicatedthatCBCmayhaveaprotectiveeffectagainstAKI.InastudypublishedintheJournalofPharmacologyandExperimentalTherapeutics,researchersfoundthatCBCtreatmentreducedkidneyinflammationandoxidativestressinratswithAKI.ThissuggeststhatCBCmayhavepotentialasatherapeuticagentforthiscondition.

Overall,thepotentialbenefitsofCBCforkidneydiseasesmakeitavaluableareaofresearchforthedevelopmentofnewtreatments.Furtherstudiesareneededtoexploreitssafetyandefficacy,aswellasitsmechanismsofactionandoptimaldosingregimens.Nevertheless,thepromisingresultsofearlystud